Superior renal benefits of SGLT2 inhibitors in type 2 diabetes highlighted in comparative study
Initiating treatment with a sodium–glucose cotransporter-2 (SGLT2) inhibitor rather than a glucagon-like peptide-1 receptor agonist (GLP-1RA) is associated with better renal outcomes in people with type 2 diabetes, according to…